Monotherapy for low-risk gestational trophoblastic neoplasia with score 5-6

Li Kemin; Zhang Mengpei; Yin Rutie

doi:10.3389/fonc.2022.1035170

Monotherapy for low-risk gestational trophoblastic neoplasia with score 5-6

Front Oncol. 2022 Nov 9:12:1035170. doi: 10.3389/fonc.2022.1035170. eCollection 2022.

Authors

Li Kemin^{1

2}, Zhang Mengpei^{1

2}, Yin Rutie^{1

2}

Affiliations

¹ The Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, Sichuan, China.
² Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, Sichuan, China.

Abstract

Objective: To investigate the monotherapy for gestational trophoblastic neoplasia (GTN) patients with FIGO/WHO prognostic score of 5-6.

Methods: The low-risk GTN patients from 2012 to 2019 were enrolled. The study is a retrospective report to analyze the efficacy and safety of single-agent chemotherapy and combination chemotherapy in patients with a high FIGO/WHO prognostic score of 5-6.

Results: 75 cases (33.5%) were included. Complete remission was in all patients. Among the 29 cases taking single-agent chemotherapy, 22 cases (75.9%) developed drug resistance. Among the 46 cases taking combination chemotherapy, 7 patients (15.2%) developed drug resistance. There was a statistically significant difference in the drug resistance rate between these two subgroups (P < 0.05), but there was not statistically significant difference in the total number of chemotherapy courses (<2mIU/ml) (P < 0.05).

Conclusion: Monotherapy showed remarkable advantages in GTN patients with FIGO/WHO prognostic score of 5-6.

Keywords: FIGO/WHO prognostic score; combination chemotherapy; gestational trophoblastic neoplasia (GTN); monotherapy for GTN with score 5-6 monotherapy showed remarkable advantages low-risk; single-agent chemotherapy.